Attacking COVID-19 Virus Hiding in the Gastrointestinal Tract of Long-Haulers with James Sapirstein AzurRx BioPharma

James Sapirstein, President and CEO, AzurRx BioPharma, a clinical stage biopharmaceutical company specializing in therapies for gastrointestinal diseases talks about turning their focus to the virus that causes COVID-19. With a background in drug development for HIV and infectious diseases, James describes their approach to developing an oral agent targeted to COVID-19 long-haulers. AzurRx is working on an indication for COVID-19 of gastrointestinal issues that is showing that the Sars-CoV-2 virus stores itself in the reservoirs inside the human body including the gastrointestinal tract.

@azurrx #AzurRxBioPharma #COVID19 #GIDrugs #GIDiseases #COVIDLongHaulers $AZRX

Download the transcript here

Share on facebook
Share on twitter
Share on linkedin
Related Post


Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.